Alzheimer’s patent dismissed

Information provided on a class of antibodies for treatment of Alzheimer’s disease and related disorders involving amyloid plaques in the brain, was judged insufficient to make it plausible for a patent. In addition clinical trials conducted after the patent filing date showed the invention was not effective for the claimed use.

Leave a Reply